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ABSTRACT
The plasminogen activation cascade is an important proteolytic pathway involved in
the growth and spread of cancer. Potentially, an inhibitor of plasminogen activation
could make an excellent cancer imaging agent or cancer treatment. The aim of this
thesis was to assess whether plasminogen activator inhibitor 2 (PAI-2) can image or
treat colorectal cancer. The first part of this thesis examined the ability of PAI-2 to
bind specifically to the human colorectal cancer cell line HCT116,

These

experiments involved confirmation of u-PA expression by HCT116 cells and cell
binding studies with ^^^I-PAI-2. The second part was examining the biodistribution
and kinetics of '^^I-PAI-2 in nude mice bearing tumour xenografts derived from
HCT116 cells. The final part involved examining the effect PAI-2 treatment had on
mice bearing HCTl 16 tumour xenografts.

PAI-2 was found to bind specifically to u-PA on HCTl 16 cells. There appeared to be
a high tumover rate of bound PAI-2 because it was difficult to detect ^^^I-PAI-2/u-PA
complexes by autoradiography.

'^^I-PAI-2 had a biphasic distribution in the

bloodstream of control mice (distribution phase (Ti/2a) 12.5min, elimination phase
(Ti/2p) 342min) and mice bearing tumour xenografts (Tyia 1.4min, Ti/2p 29min).
Approximately 1% of

I-PAI-2 localised to the tumour xenograft after a single

intravenous injection. However, more '^^I-PAI-2 could be localised to the tumour by
multiple intravenous injections. From three separate therapy experiments with PAI-2,
there did not appear to be any effect on relatively large tumours. However, in one
iii

experiment PAI-2 injections did cause two 1mm tumours to disappear. In conclusion,
PAI-2 does bind to u-PA on HCTl 16 cells in vitro. In vivo, injected PAI-2 appeared
unsuitable for the imaging of tumours or metastasis. However preliminary data from
this thesis suggest that PAI-2 may have therapeutic potential against smaller tumours.
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